GLB 005
Alternative Names: GLB-005Latest Information Update: 15 Apr 2024
At a glance
- Originator GluBio Therapeutics
- Class Antianaemics; Small molecules
- Mechanism of Action WIZ protein degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Beta-thalassaemia; Sickle cell anaemia
Most Recent Events
- 05 Apr 2024 Early research in Beta-thalassaemia in USA (unspecified route) prior to April 2024 (GluBio Therapeutics pipeline, April 2024)
- 05 Apr 2024 Early research in Sickle cell anaemia in USA (unspecified route) prior to April 2024 (GluBio Therapeutics pipeline, April 2024)